What is CODX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CODX?

P/E (TTM) is n/a and 52-week range is $0.75 to $46.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CODX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CODX?

The company profile lists revenue (TTM) near $884K, net income (TTM) near $-5.77B, EPS (TTM) near $-23.84 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Co-Diagnostics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Salt Lake City, Utah, US, 5.3M shares outstanding, ISIN US1897632048 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Co-Diagnostics Inc

$CODX

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$0.66

-8.03%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 115 full-time employees. The company went IPO on 2017-07-12. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

Employees

115

Website

codiagnostics.com/

IPO

2017-07-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)